Wegner Kelby W, Saleh Danish, Degterev Alexei
Master of Science in Biomedical Sciences Program, Tufts University School of Medicine, Boston, MA 02111, USA.
Medical Scientist Training Program and Program in Neuroscience, Sackler Graduate School, Tufts University, Boston, MA 02111, USA.
Trends Pharmacol Sci. 2017 Mar;38(3):202-225. doi: 10.1016/j.tips.2016.12.005. Epub 2017 Jan 23.
A process of regulated necrosis, termed necroptosis, has been recognized as a major contributor to cell death and inflammation occurring under a wide range of pathologic settings. The core event in necroptosis is the formation of the detergent-insoluble 'necrosome' complex of homologous Ser/Thr kinases, receptor protein interacting kinase 1 (RIPK1) and receptor interacting protein kinase 3 (RIPK3), which promotes phosphorylation of a key prodeath effector, mixed lineage kinase domain-like (MLKL), by RIPK3. Core necroptosis mediators are under multiple controls, which have been a subject of intense investigation. Additional, non-necroptotic functions of these factors, primarily in controlling apoptosis and inflammatory responses, have also begun to emerge. This review will provide an overview of the current understanding of the human disease relevance of this pathway, and potential therapeutic strategies, targeting necroptosis mediators in various pathologies.
一种被称为坏死性凋亡的程序性坏死过程,已被认为是在广泛病理情况下发生的细胞死亡和炎症的主要促成因素。坏死性凋亡的核心事件是同源丝氨酸/苏氨酸激酶、受体相互作用蛋白激酶1(RIPK1)和受体相互作用蛋白激酶3(RIPK3)形成去污剂不溶性的“坏死小体”复合物,该复合物促进RIPK3对关键促死亡效应蛋白混合谱系激酶结构域样蛋白(MLKL)的磷酸化。核心坏死性凋亡介质受到多种调控,这一直是深入研究的主题。这些因子的其他非坏死性凋亡功能,主要是在控制细胞凋亡和炎症反应方面,也已开始显现。本综述将概述目前对该通路与人类疾病相关性的理解,以及针对各种病理情况下的坏死性凋亡介质的潜在治疗策略。